Trial Announcement [pdf]
The BCC is excited to announce the start of the TARGIT-US Registry Trial, a national registry trial that evaluates the use of targeted intraoperative radiation therapy (IORT). Spearheaded by UCSF's own Dr. Michael Alvarado, the national TARGIT-US Registry Trial is now enrolling at UCSF, John Muir Medical Center, Columbia University Medical Center and Mercy Medical Center and will soon be open to accrual at over 20 sites across the nation.
The UCSF Breast Care Center is a nationally recognized leader in breast cancer research. Our clinicians are actively engaged in studies to advance all aspects of breast care including prevention, diagnosis, treatment and improving quality of life. They are also engaged in designing new processes for health care delivery, customized to the needs of individual breast cancer patients.
Reprinted by permission from MacMillan Publishers, Ltd.,
Nature Reviews Cancer 5, 591-602 (August 2005)*
Clinical trials are research studies looking at new medical interventions in people. They allow new and improved options for care to be evaluated in a controlled setting before they are made available to all patients. Every advance in breast cancer care has been the result of a clinical trial. By participating in trials, patients have access to the latest medical knowledge about breast cancer and, for those who are no longer responding to standard treatment, the opportunity to receive experimental treatment. Our physicians encourage patients to consider clinical trials as an option for care as a potential benefit for themselves as well as for the extended breast cancer community.
Developed at the UCSF Breast Care Center, BreastCancerTrials.org or BCT.org is a nationwide, clinical trial matching service that can help you find trials personalized to your situation. You can use the BCT.org matching service as a one-time guest or save your health history for continued matching. As an option, you can subscribe to the BCT.org Trial Alert Service in order to be notified whenever newly added trials match your history.
If you have never had breast cancer, but are interested in participated in a screening or prevention trial, use BCT.org to get a quick view of trials you may join:
This page contains information about breast cancer clinical trials that are currently open at UCSF. Once you have viewed the description, you can call (877) UCSF.CCC (877-827-3222) to speak to someone about whether you might be able to participate in a particular trial, or send an email with your questions or requests for more information.
In addition to clinical trials, UCSF Breast Care Center investigators are involved in other types of breast cancer research. There are several long term research projects underway with UCSF Breast Care Center physicians as leaders:
The Athena Breast Health Network is a recently-launched breast cancer prevention and treatment program that unites physicians, researchers, and patients at the five University of California medical centers, the UCSF Institute for Health Policy Studies, and the School of Public Health at UC Berkeley. We aim to reduce the number of women who develop breast cancer, to improve the survival of those women with aggressive forms of the disease, and to spare women with low-risk cancers the harmful effects of overtreatment by driving innovation in care. Therefore, the first group of women participating in Athena as patients will not have breast cancer when entering the network.
Today most women with breast cancer receive standard chemotherapy. We know that some breast cancers respond well to standard chemotherapy but some do not. The I-SPY 2 TRIAL (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2) is a clinical trial for women with newly diagnosed locally advanced breast cancer to test whether adding investigational drugs to standard chemotherapy is better than standard chemotherapy alone before having surgery.
* Figure reprinted by permission from Macmillan Publishers Ltd: Britta Weigelt, Johannes L. Peterse, Laura J. van't Veer, Nature Reviews Cancer 5, 591-602 (August 2005), Figure 4.